Ranking Vaccines: Applications of a Prioritization Software Tool: Phase III: Use Case Studies and Data Framework | Agenda Bookshop Skip to content
Black Friday Sale Now On! | Buy 3 Get 1 Free on all books | Instore & Online.
Black Friday Sale Now On! | Buy 3 Get 1 Free on all books | Instore & Online.
A01=Board on Global Health
A01=Board on Population Health and Public Health Practice
A01=Committee on Identifying and Prioritizing New Preventive Vaccines for Development
A01=Institute of Medicine
A01=National Academy of Engineering
A01=Phase III
Age Group_Uncategorized
Age Group_Uncategorized
Author_Board on Global Health
Author_Board on Population Health and Public Health Practice
Author_Committee on Identifying and Prioritizing New Preventive Vaccines for Development
Author_Institute of Medicine
Author_National Academy of Engineering
Author_Phase III
automatic-update
B01=Charles Phelps
B01=Guruprasad Madhavan
B01=Lonnie King
B01=Rino Rappuoli
B01=Rose Marie Martinez
Category1=Non-Fiction
Category=MBGR
COP=United States
Delivery_Delivery within 10-20 working days
Language_English
PA=Available
Price_€50 to €100
PS=Active
softlaunch

Ranking Vaccines: Applications of a Prioritization Software Tool: Phase III: Use Case Studies and Data Framework

SMART Vaccines - Strategic Multi-Attribute Ranking Tool for Vaccines - is a prioritization software tool developed by the Institute of Medicine that utilizes decision science and modeling to help inform choices among candidates for new vaccine development. A blueprint for this computer-based guide was presented in the 2012 report Ranking Vaccines: A Prioritization Framework: Phase I. The 2013 Phase II report refined a beta version of the model developed in the Phase I report.

Ranking Vaccines: Applications of a Prioritization Software Tool: Phase III: Use Case Studies and Data Framework extends this project by demonstrating the practical applications of SMART Vaccines through use case scenarios in partnership with the Public Health Agency of Canada, New York State Department of Health, and the Serum Institute of India. This report also explores a novel application of SMART Vaccines in determining new vaccine product profiles, and offers practical strategies for data synthesis and estimation to encourage the broader use of the software.

Table of Contents
  • Front Matter
  • Summary
  • 1 Introduction: SMART Vaccines and Smart Priorities
  • 2 Data Synthesis and Framework
  • 3 Use Case Scenarios and Design Enhancements
  • 4 Reflections and Looking Forward
  • References
  • Appendix A: Use Case Scenarios Report for SMART Vaccines
  • Appendix B: Committee's Response to the Use Case Scenarios Report
  • Appendix C: SMART Vaccines Software Updates
  • Appendix D: Stakeholder Speakers
  • Appendix E: Biographical Information
See more
Current price €71.24
Original price €74.99
Save 5%
A01=Board on Global HealthA01=Board on Population Health and Public Health PracticeA01=Committee on Identifying and Prioritizing New Preventive Vaccines for DevelopmentA01=Institute of MedicineA01=National Academy of EngineeringA01=Phase IIIAge Group_UncategorizedAuthor_Board on Global HealthAuthor_Board on Population Health and Public Health PracticeAuthor_Committee on Identifying and Prioritizing New Preventive Vaccines for DevelopmentAuthor_Institute of MedicineAuthor_National Academy of EngineeringAuthor_Phase IIIautomatic-updateB01=Charles PhelpsB01=Guruprasad MadhavanB01=Lonnie KingB01=Rino RappuoliB01=Rose Marie MartinezCategory1=Non-FictionCategory=MBGRCOP=United StatesDelivery_Delivery within 10-20 working daysLanguage_EnglishPA=AvailablePrice_€50 to €100PS=Activesoftlaunch
Delivery/Collection within 10-20 working days
Product Details
  • Dimensions: 178 x 254mm
  • Publication Date: 20 Mar 2015
  • Publisher: National Academies Press
  • Publication City/Country: United States
  • Language: English
  • ISBN13: 9780309304030

Customer Reviews

Be the first to write a review
0%
(0)
0%
(0)
0%
(0)
0%
(0)
0%
(0)
We use cookies to ensure that we give you the best experience on our website. If you continue we'll assume that you are understand this. Learn more
Accept